Quick Heal Technologies Ltd. Q4FY18 Result Update

Improvement in all parameters continues

Quick Heal Technologies (QHTL), after several quarters of consistent flat to negative revenue growth and pressure on margins, has reported a strong recovery both in terms of topline growth and margin improvement. Overall net revenue grew by 29% YoY to INR 119 cr, higher than our expectations of INR 101 cr and highest in last two years. Growth in topline was mainly supported by 33% growth in new license sales whereas realization got impacted due to GST pass on and change in product mix. The company has also taken significant cost rationalization measures in the recent past and due to that EBITDA margin improved to 55% in Q4FY18 as compared to 40% in the corresponding quarter. Supported by higher growth in H2FY18 and huge control on cost, for the full year of FY18 EBITDA margin came at 39% against our expectations of 35%. QHTL, through its' across the value chain product portfolio and extensive distribution network achieved market leadership in consumer security segment and is replicating the model to get success in the enterprise security space. We believe the underlying strength of the business remains strong and reiterate our 'BUY' recommendation with a revised target price of INR 390.

In Consumer Security space, volumes came back strongly; Realizations impacted by GST

QHTL's consumer security business (75% of overall revenue in Q4FY18) reported growth of 27% YoY baked by New license sales growth (volume growth) of 32% YoY. Re-stocking at the dealer levels post GST boosted the growth. This is the highest volume growth the company reported in the consumer business since listing. In a market with weak demand sentiment, management has taken the GST affect on them rather than passing it on to the customer and hence consumer product realization decreased by 1% in Q4FY18. The management has taken significant initiatives to reposition the consumer securities business by restructuring the distributor driven model and spend more money on brand building over the last few quarters. We believe, retail business of the company would grow at 12% CAGR over FY18-20E to INR 345 cr backed by 11% volume growth and 1% realization improvement.

Enterprise Business reported 37% YoY growth; Expected to maintain momentum going forward

Enterprise business (25% of overall revenue Q4FY18) de-grew by 3% YoY. Although, new license sales grew by 31% YoY; change in product mix affected the realization and that in-turn affected the overall growth. For the full Year of FY18, Enterprise business grew by 14% YoY backed by 23% growth in new license sales. Going forward, management is more confident of growing the B2B business to reach 50% of the overall topline in next three years as compared to 17% in FY17. India has a large base of over 5 cr SMBs and ease of installation, use, and management of security systems are absolutely essential to penetrate them. QHTL, under the 'Seqrite Brand', launched products targeted towards SMBs and emerging enterprises which are cloud enabled and able to fulfill the simple requirement of small companies and partnered with more than 490 system integrators to reach to the masses. With the higher acceptance of Seqrite brand among new age enterprises; QHTL's enterprise segment is expected to grow at 30% CAGR over FY18-20E to reach INR 107 cr in FY20E.

Strong Cash Profit generation, RoCE came back to 31% in FY18

With improvement in profitability, QHTL generated Cash profit of INR106 cr in FY18 as compared to INR 90 cr generated in FY17. Overall cash balance, increased to INR 463 cr against INR 384 cr in FY17. Most importantly, core RoCE (without considering the cash balance), after three consecutive years of continuous fall, came back to 30% levels in FY18. Going forward, core RoCE is expected to reach to 34% in FY20E mainly due to growth in profitability and improvement in working capital cycle.

Underlying Strength of the business remains intact; Reiterate BUY

At the current market price of INR 324, QHTL is trading at 19x of FY20E expected EPS of INR 17. We reiterate our 'BUY' rating with a target price of INR 380.

Financials	Q4FY18	Q4FY17	%Change	Q3FY18	%Change	FY17	FY18	FY19E	FY20E
Net Revenues (INR cr)	119	92	29%	64	85%	299	316	359	416
EBITDA (INR cr)	65	37	79%	11	471%	97	124	147	175
PAT (INR cr)	49	22	122%	7	640%	64	86	99	120
Diluted EPS (INR)						9.1	12.3	14.1	17.1
Diluted PE (x)						38.4	28.8	22.9	18.9
EV/EBITDA						19.4	15.2	12.8	10.8
ROE(%)						8%	12%	13%	14%

CMP INR: 324 Rating: BUY

Target Price INR: 390 Upside: 20%

Debashish Mazumdar

Research Analyst

debashish.mazumdar@edelweissfin.com

Bloomberg:	QUICKHEA:IN
52-week range (INR):	404.00 / 172.20
Share in issue (cr):	7.0
M cap (INR cr):	2,396
Avg. Daily Vol. BSE/NSE : ('000):	500
Promoter Holding (%)	72.50

Date: 14th May 2018

Quick Heal Technologies Ltd.

Q4FY18 Result Highlights

	Q4FY18	Q4FY17	%Change	Q3FY18	%Change	FY18	FY17	%Change
Net Revenues	119	92	29%	64	85%	316	299	6%
Direct Expenses	6	6	5%	4	77%	16	22	-24%
Gross Profit	112	86	30%	61	85%	300	277	8%
Operating Expenses	47	50	-5%	49	-5%	176	180	-2%
EBITDA	65	37	79%	11	471%	124	97	27%
Depreciation	7	8	-15%	7	2%	27	31	-13%
Interest	0	0	-	0	-	0	0	-
Other Income	14	6	117%	5	159%	30	28	8%
PBT	72	35	108%	10	630%	127	94	35%
Tax Payment	23	12	84%	3	610%	40	31	32%
PAT Before Extraordinary	49	22	122%	7	640%	86	64	36%
Extraordinary Items	0	0	-	0	-	-8	-4	70%
Reported PAT	49	22	122%	7	640%	79	59	33%
Equity Capital	70	70	-	71	-	70	70	-
No of Shares	7	7	-	7	-1%	7	7	-
EPS	7.0	3.2	122%	0.94	650%	11.3	8.5	33%
EBITDA Margin	55%	40%		18%		39%	33%	
PAT Margin	41%	24%		10%		25%	20%	
Tax Rate	32%	36%		33%		32%	32%	

Other Key Highlights

- QHTL has active licenses base of 84 lakhs at the end of FY18 as copared to 78 lakhs of active licenses in FY17.
- In the retail segment, the company is now having 21,401 chennel partners selling products at different parts of India. In the enterprise srgment, the company currently has 527 enhtrprise partners.
- In the enterprise segment, the company added 5000 new clients in FY18 and currently has 30,000 active clients. The company added more than 100 new customers where average users are more than 500.
- Recenuevable days without GST has come to 101 days in FY18 which was lower than the previous years debtor cycle of 111 days.
- R&D spending in FY18 came at INR 57 cr, 11% de-growth as comapred to FY17. R&D spending as percentage of revenue came down to 18% as comapred to 21% in FY17. Going forward, management is confident of maintaining R&D spending at 18-20% range.
- In the retail business costomer retaintion ratio was 35% whereas for enterprise business retention wss 75% in FY18. Management is targeting to improve the retention ratio of enterprise segment to 90%.

2 GWM

Quick Heal Technologies Ltd.

Financials

Income statement					(INR cr)
Year to March	FY16	FY17E	FY18E	FY19E	FY20E
Income from operations	302	299	316	359	416
Direct Expenses	28	22	16	19	22
R&D Expenses	59	64	57	60	69
SG&A Expenses	113	117	119	133	151
Total operating expenses	200	202	192	212	242
EBITDA	102	97	124	147	175
Depreciation and amortisation	24	31	27	30	32
EBIT	78	66	97	117	143
Interest expenses	0	0	0	0	0
Otherincome	10	28	30	31	37
Profit before tax	88	94	127	148	179
Provision for tax	30	31	40	49	59
Core profit	58	64	86	99	120
Extraordinary items	0	0	0	0	0
Profit after tax	58	64	86	99	120
Minority Interest	0	0	0	0	0
Share from associates	0	0	0	0	0
Adjusted net profit	58	64	86	99	120
Equity shares outstanding (Crs)	7.0	7.0	7.0	7.0	7.0
EPS (INR) basic	8.3	9.1	12.3	14.1	17.1
Diluted shares (Crs)	7.0	7.0	7.0	7.0	7.0
EPS (INR) fully diluted	8.3	9.1	12.3	14.1	17.1
Dividend per share	2.5	2.5	2.5	3.0	3.0
Dividend payout (%)	0.3	0.3	0.2	0.2	0.2

Common size metrics- as % of net revenues

Year to March	FY16	FY17E	FY18E	FY19E	FY20E
Operating expenses	66.3	67.5	60.9	59.0	58.0
Depreciation	7.8	10.3	8.5	8.3	7.7
Interest expenditure	0.0	0.0	0.0	0.0	0.0
EBITDA margins	33.7	32.5	39.1	41.0	42.0
Net profit margins	19.2	21.3	27.3	27.7	28.8

Growth metrics (%)

Year to March	FY16	FY17E	FY18E	FY19E	FY20E
Revenues	14.5	(1.0)	5.8	13.4	16.1
EBITDA	11.0	(4.6)	27.2	18.7	18.9
PBT	10.4	6.8	34.6	16.8	21.0
Net profit after minority interest	7.7	9.7	35.9	14.8	21.0
EPS	(6.1)	9.6	35.3	14.8	21.0

Profit & Efficiency Ratios

rioni & Enicieticy Ranos					
Year to March	FY16	FY17E	FY18E	FY19E	FY20E
ROAE (%)	12%	8%	12%	13%	14%
ROACE (%)	19%	14%	18%	19%	20%
Debtors (days)	103	116	118	114	111
Current ratio	4.5	7.1	10.6	10.5	10.5
Debt/Equity	0.0	0.0	0.0	0.0	0.0
Inventory (days)	8	10	6	7	7
Payable (days)	64	50	38	35	35
Cash conversion cycle (days)	47	76	87	86	83
Debt/EBITDA	0.0	0.0	0.0	0.0	0.0
Adjusted debt/Equity	0.0	0.0	0.0	0.0	0.0

Valuation parameters

Year to March	FY16	FY17E	FY18E	FY19E	FY20E
Diluted EPS (INR)	8.3	8.4	11.3	14.2	17.1
Y-o-Y growth (%)	7.7	2.1	33.3	25.8	21.0
CEPS (INR)	11.7	12.9	15.1	18.4	21.7
Diluted P/E (x)	39.2	38.4	28.8	22.9	18.9
Price/BV(x)	3.7	3.4	3.1	2.7	2.4
EV/Sales (x)	6.2	6.3	6.0	5.3	4.5
EV/EBITDA (x)	18.5	19.4	15.2	12.8	10.8
Diluted shares O/S	7.0	7.0	7.0	7.0	7.0
Basic EPS	8.3	9.1	12.3	14.1	17.1
Basic PE (x)	39.2	38.4	28.8	22.9	18.9
Dividend yield (%)	1%	1%	1%	1%	1%

Balance sheet					(INR cr)
As on 31st March	FY16	FY17E	FY18E	FY19E	FY20E
Equity share capital	70	70	70	70	70
Warrants	0	0	0	0	0
Reserves & surplus	537	592	653	727	822
Shareholders funds	607	662	724	798	892
Borrowings	0	2	2	2	2
Minority interest	0	0	0	0	0
Sources of funds	607	664	726	800	895
Gross block	206	277	331	371	401
Depreciation	64	92	119	149	181
Net block	142	185	212	222	220
Capital work in progress	55	14	14	14	14
Total fixed assets	197	198	226	236	234
Goodwill	0	0	0	0	0
Non Current Assets	29	41	15	15	15
Current Investments	108	175	451	501	551
Sundry debtors	95	97	103	109	126
Cash and equivalents	269	209	12	14	41
Loans and advances	9	1	1	12	24
Other current assets	9	12	12	14	15
Total current assets	490	495	579	650	756
Sundry creditors and others	68	70	55	62	72
Provisions	41	0	0	0	0
Total CL & provisions	108	70	55	62	72
Net current assets	382	425	524	588	685
Net Deferred tax	0	0	0	0	0
Misc expenditure	0	0	0	0	0
Uses of funds	607	664	726	800	895
Book value per share (INR)	87	95	103	114	127

Cash flow statement					(INR cr)
Year to March	FY16	FY17E	FY18E	FY19E	FY20E
Net profit	58	64	86	99	120
Add: Depreciation	24	31	27	30	32
Add: Misc expenses written off	0	0	0	0	0
Add: Deferred tax	-2	0	0	0	0
Add: Others	-9	0	0	0	0
Gross cash flow	70	94	113	129	152
Less: Changes in W.C.	22	36	21	11	20
Operating cash flow	48	58	93	117	132
Less: Capex	36	30	55	40	30
Free cash flow	12	28	38	77	102

3 GWM

Edelweiss Broking Limited, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W) Board: (91-22) 4272 2200

Vinay Khattar

Head Research

vinay.khattar@edelweissfin.com

Rating	Expected to
Buy	appreciate more than 15% over a 12-month period
Hold	appreciate between 5-15% over a 12-month period
Reduce	Return below 5% over a 12-month period



4 GWM

Disclaimer

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: complianceofficer.ebl@edelweissfin.com Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH00000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Post performance is not necessarily a guide to future performance. The dis

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under

Disclaimer

applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.